Advertisement


David A. Williams, MD, on the Goals and Highlights of ASH 2015

2015 ASH Annual Meeting

Advertisement

Outgoing ASH President, David A. Williams, MD, of the Dana-Farber/Boston Children’s Hospital, gives an overview of this year’s Annual Meeting of the American Society of Hematology.



Related Videos

Lymphoma

Laurie H. Sehn, MD, MPH, on Classical HL: New Findings on the Need for Radiotherapy

Laurie H. Sehn, MD, MPH, of the British Columbia Cancer Agency, discusses a study that showed patients with advanced-stage classical Hodgkin lymphoma, with a negative PET-scan following ABVD chemotherapy, have excellent outcomes without the need for consolidative radiotherapy, regardless of disease bulk at presentation (Abstract 579).

Leukemia

Sébastien Maury, MD, on ALL: Results of the Graall-R 2005 Study

Sébastien Maury, MD, of the Hôpital Henri Mondor, discusses this study in which adding rituximab improved the outcome of adult patients with CD20-positive, Ph-negative B-cell precursor acute lymphoblastic leukemia (Abstract 1). To see the French language version of this newsreel, please click here.

Lymphoma

Olivier Casasnovas, MD, on Advanced-Stage Hodgkin Lymphoma: Interim Analysis of the Lysa Study (French Language Version)

Olivier Casasnovas, MD, of Hôpital Le Bocage, discusses in French a phase III study comparing an early PET-driven treatment de-escalation to a not PET-monitored strategy in patients with advanced Hodgkin lymphoma (Abstract 577).

Lymphoma

Kieron Dunleavy, MD, on Burkitt Lymphoma: Preliminary Report of the DA-EPOCH-R Trial

Kieron Dunleavy, MD, of the National Cancer Institute, discusses a multi-center trial that set out to validate the effectiveness of DA-EPOCH-R-based therapy and whether a risk-adapted approach using the regimen is beneficial for patients with Burkitt lymphoma (Abstract 342).

Lymphoma

Jonathon Cohen, MD, on Deferring MCL Treatment

Jonathon B. Cohen, MD, of the Winship Cancer Institute, discusses a study that used the National Cancer Data Base to study the impact on overall survival of deferring treatment in patients with newly diagnosed mantle cell lymphoma (Abstract 2717).

Advertisement

Advertisement




Advertisement